gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · GILDHealthcareBiotechnology

Gilead Sciences Inc (GILD)

$174.48+4.19%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$174.28▲ 42.80% in range
Nov 3, 2025Low $118.15 · High $174.28Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Gilead Sciences closed at $174.48 on Nov 4, up 4.19% — matching its 52-week closing high. Volume of 9.6M shares was 1.46× its 20-day average (above normal).

Split-adjusted performance: +21.0% over one month, +28.0% over six months, +43.0% over one year.

In the quarter ended Sep 30, 2026, revenue was $8.30B, up 6.8% from a year earlier, with a net margin of 29.3%.

Short interest was 20.3M shares at the Oct 15 settlement, down 7.1% from the prior report (1.6% of float, 3.7 days to cover).

Market cap$216.41B1.24B shares
Revenue · quarter$8.30B+6.8% YoY
Diluted EPS$1.94−20.2% YoY
P/E · TTM—P/S 7.0×
Net margin29.3%Gross 81.1%
Dividend yield1.88%$0.82 last paid
52-week range118.15 – 174.480.0% from high
Volume9.6M1.46× 20-day avg
Volatility · 60d26.6%Annualised
Short % of float1.6%3.7 days to cover
Net cash-$19.79BCash $6.44B
Next earnings—Not scheduled
Split-adjusted performance
1W +9.6%1M +21.0%3M +33.3%6M +28.0%YTD +42.2%1Y +43.0%3Y +124.4%5Y +161.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum82
Revenue growth47
Net margin86
Value (low P/E)—
Size99

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short20.3M−7.1% vs prior
Days to cover3.7Settled Oct 15
% of float1.6%
Short vol. 10d47.6%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
GILDGilead Sciences$174.48+4.19%+28.0%+6.8%29.3%—$216.41B
AMGNAmgen$478.48+3.73%+44.5%+9.5%23.6%29.6$258.68BCompare
MRNAModerna$258.38+13.11%+429.6%+2.1%−539.3%—$103.15BCompare
RVMDRevolution Medicines$199.70+2.82%+32.2%———$42.80BCompare
BIIBBiogen$254.46+2.22%+33.4%+10.6%−0.7%108.2$37.61BCompare
EXELExelixis$72.75+0.61%+49.4%+10.2%33.1%20.1$17.75BCompare
NBIXNeurocrine Biosciences$166.05+0.73%+12.9%+41.2%18.4%24.0$16.88BCompare
HALOHalozyme Therapeutics$130.34+1.34%+96.4%+47.7%47.8%35.8$14.79BCompare
KYMRKymera Therapeutics$136.25+7.21%+58.0%−100.0%——$11.63BCompare

News about Gilead Sciences

All news →
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on ItZacks Investment Research · 17h agoNeutral1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in NovemberThe Motley Fool · 3d ago▲ PositiveGILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthZacks Investment Research · 5d ago▲ PositiveGILD Q3 Earnings Call Highlights Raised Outlook and Pricing RisksZacks Investment Research · 5d ago▲ PositiveGilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research · 6d ago▲ Positive

Quick answers

What does Gilead Sciences do?
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care.
What is GILD's market cap?
$216.41B, based on the Nov 4 close of $174.48.
Does Gilead Sciences pay a dividend?
Yes. The latest regular dividend was $0.82 per share (ex-date Sep 15), an annualised yield of 1.88%.
How much of GILD is sold short?
20.3M shares, 1.6% of float, as of Oct 15, 2026.
What sector is GILD in?
Healthcare, in the Biotechnology industry.

About Gilead Sciences

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

HQ: Foster City, CA17,000 employeesListed Jan 22, 1992gilead.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology